long intergenic non-protein coding RNA 1235Genealiases: []
Q-omics provides the consensus-scored LINC01235 profile across patient tissues and cancer cell-line models. LINC01235 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LINC01235 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LINC01235 RNA expression shows 13,876 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, KIRC, and THYM as cancer lineages where LINC01235 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01235 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01235 survival associations across molecular data types. LINC01235 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01235 RNA expression–survival associations across cancer types. High LINC01235 expression shows unfavorable associations in BRCA, STAD, CESC, LGG and UCEC, but favorable associations in KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for LINC01235 RNA expression.
This table summarizes LINC01235 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01235. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01235 shows lower tumor expression in BRCA and higher tumor expression in KIRC, COAD, LIHC, LUAD and READ. The KIRC box plot shows higher LINC01235 RNA expression in tumor versus normal tissue (log2 FC = +2.309, t-test p < 0.001).
This table shows molecular features associated with LINC01235 in patient tissues and cancer cell lines. In patient samples, LINC01235 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
